<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00280384</url>
  </required_header>
  <id_info>
    <org_study_id>E2014-J081-133</org_study_id>
    <nct_id>NCT00280384</nct_id>
  </id_info>
  <brief_title>An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects</brief_title>
  <official_title>An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      To evaluate inter-ethnic similarity in pharmacodynamics between Japanese and Caucasian
      healthy adult male subjects by comparing electrophysiological reactions after administering
      E2014 to extensor digitorum brevis muscle (EDB).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
    <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave amplitude induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave amplitudes (mV) were measured at screening (baseline), and Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, Day 14, Week 4, and Week 12. Rates of EDB M-wave amplitude reduction from baseline were then calculated at each time point. The maximum rates of EDB M-wave amplitude reduction from baseline were presented as a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave amplitude induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave amplitudes (mV) were measured at screening (baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Area Reduction From Baseline</measure>
    <time_frame>Baseline and Up to 12 Weeks</time_frame>
    <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave area induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave area (mVms) was measured at screening (baseline), and Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, Day 14, Week 4, and Week 12. Rates of EDB M-wave area reduction from baseline were then calculated at each time point. The maximum rates of EDB M-wave area reduction from baseline were presented as a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extensor Digitorum Brevis (EDB) Muscle M-Wave Area At Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave area induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave area (mVms) was measured at screening (baseline).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Spasmodic Torticollis</condition>
  <arm_group>
    <arm_group_label>E2014 (Botulinum toxin type B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2014 (Botulinum toxin type B) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2014 (Botulinum toxin type B)</intervention_name>
    <description>A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.</description>
    <arm_group_label>E2014 (Botulinum toxin type B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2014 (Botulinum toxin type B) Placebo</intervention_name>
    <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.</description>
    <arm_group_label>E2014 (Botulinum toxin type B) Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Participants aged between 20 and 44 years at the time of obtaining informed consent.

          2. Participants whose M wave amplitude potential (between baseline and negative peak) in
             the EDB by stimulating peroneal nerve in the foot joints is 1 mV or more during
             electrophysiological examinations at the times of screening and immediately before
             administration.

          3. Participants who are judged to be eligible for study entry by an investigator or
             subinvestigator at screening and at immediately before pre-treatment medical
             examination.

          4. Participants who are given a full explanation about the objective and details of this
             study before starting screening and give written consent based on their free will.

        Exclusion Criteria:

          1. Participants who have a complication or history of peripheral neuropathy, nerve root
             impairment, muscle disease.

          2. Participants with a disease that may influence the study drug evaluation, such as
             disorders of the gastrointestinal tract, liver, respiratory, endocrine, hematological,
             neurological, psychiatric and cardiovascular system, and congenital abnormality in
             metabolism.

          3. Participants who have accessory deep peroneal nerve.

          4. Participants who previously received a treatment with botulinum toxin.

          5. Participants with a history of hypersensitivity to any component of E2014 (human serum
             albumin, succinate buffer solution).

          6. Participants who are positive for urine drug screening at the time of screening or
             immediately before study drug administration.

          7. Participants who received prescription drug(s) within 1 month before study drug
             administration.

          8. Participants who have been treated with another investigational drug within 4 months
             before study drug administration.

          9. Participants who have experienced heavy exercise or hard labor within 2 weeks before
             study drug administration.

         10. Participants who underwent blood transfusion within 3 months before, those whose 400
             mL of whole blood was collected within 3 months before, or those whose 200 mL of whole
             blood was collected within 1 month before study drug administration.

         11. Participants who are positive for hepatitis B surface antigen (HBs antigen), hepatitis
             C virus (HCV) antibody, or serologic test for syphilis (STS).

         12. Participants who received a diagnosis of acquired immunodeficiency syndrome (AIDS) or
             those with positive result for human immunodeficiency virus.

         13. Participants who are unwilling or unable to abide by the requirements of this study,
             or those who may violate the prohibitions and restrictions of this study.

         14. Participants who are judge to be ineligible for study entry by a principal
             investigator or subinvestigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroki Shimizu</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <state>Kagoshima-prefecture</state>
        <zip>890-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2006</study_first_submitted>
  <study_first_submitted_qc>January 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2006</study_first_posted>
  <results_first_submitted>March 12, 2013</results_first_submitted>
  <results_first_submitted_qc>April 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2013</results_first_posted>
  <last_update_submitted>April 23, 2013</last_update_submitted>
  <last_update_submitted_qc>April 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>rimabotulinumtoxinB</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 94 participants screened (60 Japanese, 34 Caucasian), 57 (29 Japanese and 28 Caucasian) participants were admitted to the hospital. 9 (5 Japanese and 4 Caucasian) participants did not receive the study drug. 48 participants received the study drug (24 Japanese and 24 Caucasian) and were considered the treated population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>E2014 (Botulinum Toxin Type B) Placebo- Japanese</title>
          <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="P2">
          <title>E2014 (Botulinum Toxin Type B) 20 U - Japanese</title>
          <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="P3">
          <title>E2014 (Botulinum Toxin Type B) 100 U - Japanese</title>
          <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="P4">
          <title>E2014 (Botulinum Toxin Type B) 500 U - Japanese</title>
          <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="P5">
          <title>E2014 (Botulinum Toxin Type B) Placebo - Caucasian</title>
          <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="P6">
          <title>E2014 (Botulinum Toxin Type B) 20 U - Caucasian</title>
          <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="P7">
          <title>E2014 (Botulinum Toxin Type B) 100 U - Caucasian</title>
          <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="P8">
          <title>E2014 (Botulinum Toxin Type B) 500 U - Caucasian</title>
          <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>E2014 (Botulinum Toxin Type B) Placebo- Japanese</title>
          <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="B2">
          <title>E2014 (Botulinum Toxin Type B) 20 U - Japanese</title>
          <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="B3">
          <title>E2014 (Botulinum Toxin Type B) 100 U - Japanese</title>
          <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="B4">
          <title>E2014 (Botulinum Toxin Type B) 500 U - Japanese</title>
          <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="B5">
          <title>E2014 (Botulinum Toxin Type B) Placebo - Caucasian</title>
          <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="B6">
          <title>E2014 (Botulinum Toxin Type B) 20 U - Caucasian</title>
          <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="B7">
          <title>E2014 (Botulinum Toxin Type B) 100 U - Caucasian</title>
          <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="B8">
          <title>E2014 (Botulinum Toxin Type B) 500 U - Caucasian</title>
          <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.7" spread="2.9"/>
                    <measurement group_id="B2" value="28.0" spread="5.4"/>
                    <measurement group_id="B3" value="23.3" spread="2.9"/>
                    <measurement group_id="B4" value="22.2" spread="2.6"/>
                    <measurement group_id="B5" value="33.7" spread="2.7"/>
                    <measurement group_id="B6" value="34.5" spread="3.7"/>
                    <measurement group_id="B7" value="32.7" spread="2.9"/>
                    <measurement group_id="B8" value="29.3" spread="2.6"/>
                    <measurement group_id="B9" value="28.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline</title>
        <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave amplitude induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave amplitudes (mV) were measured at screening (baseline), and Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, Day 14, Week 4, and Week 12. Rates of EDB M-wave amplitude reduction from baseline were then calculated at each time point. The maximum rates of EDB M-wave amplitude reduction from baseline were presented as a percentage.</description>
        <time_frame>Baseline and Up to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>E2014 (Botulinum Toxin Type B) Placebo- Japanese</title>
            <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>E2014 (Botulinum Toxin Type B) 20 U - Japanese</title>
            <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>E2014 (Botulinum Toxin Type B) 100 U - Japanese</title>
            <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>E2014 (Botulinum Toxin Type B) 500 U - Japanese</title>
            <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>E2014 (Botulinum Toxin Type B) Placebo - Caucasian</title>
            <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>E2014 (Botulinum Toxin Type B) 20 U - Caucasian</title>
            <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>E2014 (Botulinum Toxin Type B) 100 U - Caucasian</title>
            <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O8">
            <title>E2014 (Botulinum Toxin Type B) 500 U - Caucasian</title>
            <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline</title>
          <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave amplitude induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave amplitudes (mV) were measured at screening (baseline), and Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, Day 14, Week 4, and Week 12. Rates of EDB M-wave amplitude reduction from baseline were then calculated at each time point. The maximum rates of EDB M-wave amplitude reduction from baseline were presented as a percentage.</description>
          <units>Percentage of Reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.02" spread="13.51"/>
                    <measurement group_id="O2" value="48.53" spread="16.98"/>
                    <measurement group_id="O3" value="70.95" spread="6.12"/>
                    <measurement group_id="O4" value="81.62" spread="7.55"/>
                    <measurement group_id="O5" value="14.33" spread="9.05"/>
                    <measurement group_id="O6" value="42.77" spread="20.78"/>
                    <measurement group_id="O7" value="50.70" spread="9.35"/>
                    <measurement group_id="O8" value="74.47" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude at Baseline</title>
        <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave amplitude induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave amplitudes (mV) were measured at screening (baseline).</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>E2014 (Botulinum Toxin Type B) Placebo- Japanese</title>
            <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>E2014 (Botulinum Toxin Type B) 20 U - Japanese</title>
            <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>E2014 (Botulinum Toxin Type B) 100 U - Japanese</title>
            <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>E2014 (Botulinum Toxin Type B) 500 U - Japanese</title>
            <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>E2014 (Botulinum Toxin Type B) Placebo - Caucasian</title>
            <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>E2014 (Botulinum Toxin Type B) 20 U - Caucasian</title>
            <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>E2014 (Botulinum Toxin Type B) 100 U - Caucasian</title>
            <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O8">
            <title>E2014 (Botulinum Toxin Type B) 500 U - Caucasian</title>
            <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude at Baseline</title>
          <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave amplitude induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave amplitudes (mV) were measured at screening (baseline).</description>
          <units>EDB M-Wave Amplitude at Baseline (mV)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="1.25"/>
                    <measurement group_id="O2" value="4.73" spread="1.13"/>
                    <measurement group_id="O3" value="4.95" spread="1.48"/>
                    <measurement group_id="O4" value="4.78" spread="1.70"/>
                    <measurement group_id="O5" value="7.12" spread="1.40"/>
                    <measurement group_id="O6" value="5.48" spread="1.92"/>
                    <measurement group_id="O7" value="6.00" spread="2.52"/>
                    <measurement group_id="O8" value="5.12" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Area Reduction From Baseline</title>
        <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave area induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave area (mVms) was measured at screening (baseline), and Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, Day 14, Week 4, and Week 12. Rates of EDB M-wave area reduction from baseline were then calculated at each time point. The maximum rates of EDB M-wave area reduction from baseline were presented as a percentage.</description>
        <time_frame>Baseline and Up to 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>E2014 (Botulinum Toxin Type B) Placebo- Japanese</title>
            <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>E2014 (Botulinum Toxin Type B) 20 U - Japanese</title>
            <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>E2014 (Botulinum Toxin Type B) 100 U - Japanese</title>
            <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>E2014 (Botulinum Toxin Type B) 500 U - Japanese</title>
            <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>E2014 (Botulinum Toxin Type B) Placebo - Caucasian</title>
            <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>E2014 (Botulinum Toxin Type B) 20 U - Caucasian</title>
            <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>E2014 (Botulinum Toxin Type B) 100 U - Caucasian</title>
            <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O8">
            <title>E2014 (Botulinum Toxin Type B) 500 U - Caucasian</title>
            <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Area Reduction From Baseline</title>
          <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave area induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave area (mVms) was measured at screening (baseline), and Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, Day 14, Week 4, and Week 12. Rates of EDB M-wave area reduction from baseline were then calculated at each time point. The maximum rates of EDB M-wave area reduction from baseline were presented as a percentage.</description>
          <units>Percentage of Reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.13" spread="17.19"/>
                    <measurement group_id="O2" value="43.22" spread="15.50"/>
                    <measurement group_id="O3" value="74.97" spread="7.60"/>
                    <measurement group_id="O4" value="79.03" spread="8.85"/>
                    <measurement group_id="O5" value="14.98" spread="12.06"/>
                    <measurement group_id="O6" value="45.65" spread="20.34"/>
                    <measurement group_id="O7" value="48.12" spread="11.09"/>
                    <measurement group_id="O8" value="75.65" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extensor Digitorum Brevis (EDB) Muscle M-Wave Area At Baseline</title>
        <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave area induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave area (mVms) was measured at screening (baseline).</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>E2014 (Botulinum Toxin Type B) Placebo- Japanese</title>
            <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>E2014 (Botulinum Toxin Type B) 20 U - Japanese</title>
            <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>E2014 (Botulinum Toxin Type B) 100 U - Japanese</title>
            <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>E2014 (Botulinum Toxin Type B) 500 U - Japanese</title>
            <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>E2014 (Botulinum Toxin Type B) Placebo - Caucasian</title>
            <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>E2014 (Botulinum Toxin Type B) 20 U - Caucasian</title>
            <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>E2014 (Botulinum Toxin Type B) 100 U - Caucasian</title>
            <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
          <group group_id="O8">
            <title>E2014 (Botulinum Toxin Type B) 500 U - Caucasian</title>
            <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Extensor Digitorum Brevis (EDB) Muscle M-Wave Area At Baseline</title>
          <description>The pharmacodynamic effect of botulinum toxin type B (E2014) was evaluated based on the inhibition of EDB M-wave area induced by stimulation of the deep peroneal nerve in the left ankles of the study participants. EDB M-wave area (mVms) was measured at screening (baseline).</description>
          <units>EDB M-Wave Area at Baseline (mVms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.90" spread="4.23"/>
                    <measurement group_id="O2" value="14.97" spread="3.80"/>
                    <measurement group_id="O3" value="14.38" spread="4.67"/>
                    <measurement group_id="O4" value="14.85" spread="4.78"/>
                    <measurement group_id="O5" value="18.68" spread="1.99"/>
                    <measurement group_id="O6" value="16.18" spread="4.03"/>
                    <measurement group_id="O7" value="17.57" spread="5.67"/>
                    <measurement group_id="O8" value="14.58" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>E2014 (Botulinum Toxin Type B) Placebo- Japanese</title>
          <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="E2">
          <title>E2014 (Botulinum Toxin Type B) 20 U - Japanese</title>
          <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="E3">
          <title>E2014 (Botulinum Toxin Type B) 100 U - Japanese</title>
          <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="E4">
          <title>E2014 (Botulinum Toxin Type B) 500 U - Japanese</title>
          <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese participants.</description>
        </group>
        <group group_id="E5">
          <title>E2014 (Botulinum Toxin Type B) Placebo - Caucasian</title>
          <description>A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="E6">
          <title>E2014 (Botulinum Toxin Type B) 20 U - Caucasian</title>
          <description>A single-dose injection solution containing 20 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="E7">
          <title>E2014 (Botulinum Toxin Type B) 100 U - Caucasian</title>
          <description>A single-dose injection solution containing 100 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
        <group group_id="E8">
          <title>E2014 (Botulinum Toxin Type B) 500 U - Caucasian</title>
          <description>A single-dose injection solution containing 500 U/ 0.2 mL of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Caucasian participants.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Neck Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White Blood Cell Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eosinophil Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophil Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hiroki Shimizu, Study Director</name_or_title>
      <organization>Eisai Co., Ltd.</organization>
      <phone>81-3-3817-5235</phone>
      <email>h3-shimizu@hhc.eisai.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

